# A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

> **NCT07630974** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 134 (estimated)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **BIOLOGICAL:** Ifinatamab Deruxtecan

## Key facts

- **NCT ID:** NCT07630974
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2031-08-17
- **Final completion:** 2031-08-17
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630974, "A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07630974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*